How Peptides Are Made: Synthesis & Quality Control

The vast majority of synthetic peptides are produced using solid-phase peptide synthesis, a method developed by Robert Bruce Merrifield in 1963, earning him the Nobel Prize in Chemistry in 1984.

The principle: Amino acids are added one at a time to a growing peptide chain that is anchored to an insoluble resin bead. This "solid phase" approach allows reagents and by-products to be washed away at each step, greatly simplifying the process.

The cycle (repeated for each amino acid): 1. Deprotection: Remove the temporary protecting group from the terminal amino acid on the resin 2. Coupling: Activate the next amino acid and react it with the free terminal amine 3. Washing: Remove excess reagents and by-products 4. Repeat: Continue until the full sequence is assembled 5. Cleavage: Detach the completed peptide from the resin and remove side-chain protecting groups

Two main chemistries: - Fmoc (fluorenylmethyloxycarbonyl): The modern standard — uses mild base for deprotection, compatible with acid-labile side-chain groups - Boc (tert-butyloxycarbonyl): The original Merrifield approach — uses acid for deprotection, requires harsh final cleavage with HF

Coupling efficiency: Each coupling step is typically 99–99.5% efficient. For a 40-amino-acid peptide, even 99.5% per-step efficiency yields only 82% full-length product. This cumulative loss is why longer peptides are more challenging and expensive to produce.

After synthesis, the crude peptide is a mixture of the desired product, deletion sequences, truncated chains, and chemical by-products. Purification is essential.

Reversed-Phase HPLC (RP-HPLC): The gold standard for peptide purification: - The peptide mixture is dissolved and passed through a column packed with hydrophobic beads (typically C18-modified silica) - Peptides bind to the column based on hydrophobicity - A gradient of increasing organic solvent (acetonitrile) elutes peptides sequentially - The desired peptide elutes at a characteristic retention time, separated from impurities - UV detection (typically at 214 nm, detecting peptide bonds) monitors the eluate

Purity grades: - Crude: Unpurified — typically 40–70% purity - Desalted (>75%): Minimal purification, suitable for some screening applications - >95% purity: Standard research grade — adequate for most in-vitro studies - >98% purity: High purity — preferred for in-vivo research - >99% purity: Pharmaceutical grade — required for clinical use

Other purification methods: - Ion-exchange chromatography for charged peptides - Size-exclusion chromatography for separating aggregates - Preparative HPLC for large-scale production

The purity grade directly affects both cost and reliability. Higher purity requires more purification steps, lower yields, and greater expense.

Purification tells you how pure the product is; mass spectrometry tells you whether the product is actually the correct peptide.

How it works: Mass spectrometry measures the mass-to-charge ratio (m/z) of ionised molecules. For peptides, the measured molecular weight is compared to the theoretical weight calculated from the amino acid sequence.

Common techniques:

MALDI-TOF (Matrix-Assisted Laser Desorption/Ionisation — Time of Flight): - The peptide is embedded in a matrix and ionised by a laser pulse - Ions are accelerated through a flight tube — lighter ions arrive at the detector first - Provides a rapid "molecular fingerprint" - Excellent for confirming identity of purified peptides

ESI-MS (Electrospray Ionisation Mass Spectrometry): - The peptide solution is sprayed through a charged needle, creating multiply charged droplets - Commonly coupled with HPLC (LC-MS) for simultaneous separation and identification - Can handle larger peptides and proteins

What the Certificate of Analysis (CoA) should show: - Observed molecular weight matching the theoretical value (within instrument tolerance, typically ±1 Da) - HPLC chromatogram showing a single major peak at the expected purity - Amino acid sequence confirmation for pharmaceutical-grade products

Red flags: - Missing or incomplete CoA - Molecular weight discrepancy of more than 2 Da - Multiple major peaks on the HPLC trace - CoA that appears generic or does not match the batch number

The manufacturing environment dramatically affects peptide quality, consistency, and safety.

Research-grade (RUO — Research Use Only): - Manufactured in standard laboratory facilities - Quality control typically limited to HPLC purity and MS identity - No formal process validation or environmental monitoring - Suitable for laboratory research — not intended for human use - Significantly less expensive than GMP production - The majority of peptides sold online fall into this category

GMP (Good Manufacturing Practice): - Manufactured in certified facilities with controlled environments (clean rooms, air handling) - Full process validation: every step is documented and reproducible - Extensive quality control: identity, purity, potency, sterility, endotoxin, residual solvents - Batch records trace every raw material and process parameter - Regular facility inspections by regulatory bodies (MHRA, FDA, EMA) - Required for any peptide intended for human clinical use

The gap in the peptide market: Many peptides available to consumers are manufactured to research-grade standards but marketed for human use. This creates a significant quality and safety concern: - No endotoxin testing (bacterial contaminants that cause fever and inflammation) - No sterility assurance for injectable products - No residual solvent analysis (synthesis solvents can be toxic) - No heavy metal testing - No validated potency assays

Approved pharmaceutical peptides (e.g., semaglutide, teriparatide) are always manufactured under GMP conditions.

Peptide manufacturing is evolving to address limitations of traditional SPPS:

Flow chemistry: - Continuous-flow SPPS systems automate the entire synthesis process - Faster cycle times and improved reproducibility - Companies like Amgen and Novo Nordisk invest heavily in flow-based production - Particularly advantageous for large-scale manufacturing of peptide drugs

Recombinant production: - Using engineered bacteria (E. coli) or yeast to produce peptides biologically - Cost-effective for longer peptides (>50 amino acids) where chemical synthesis becomes impractical - Requires downstream processing to remove host-cell proteins and endotoxins - Cannot easily produce peptides with non-natural amino acids or chemical modifications

Native chemical ligation: - Joining two or more peptide fragments to create longer sequences - Overcomes the practical length limit of SPPS (~50 amino acids) - Used in research to produce proteins that are difficult to express recombinantly

Green chemistry approaches: - Reducing the large solvent volumes used in traditional SPPS - Developing recyclable resins and less toxic coupling reagents - Water-based synthesis methods under investigation

The impact on consumers: As manufacturing technology improves, peptide production costs decrease and quality becomes more consistent. This trend is driving more peptides into formal pharmaceutical development pipelines, which ultimately benefits patients through better-characterised, more reliable products.

*This article is for educational purposes only. Research-grade peptides are not intended for human use. Only use peptides that have been prescribed by a qualified medical professional and manufactured to appropriate standards.*